Oruka Therapeutics CEO Lawrence Klein joins us to discuss how his company raised its first round of financing before competing with major players in the inflammation space. We also discuss the latest news in the life sciences, including the end of the Amylyx ALS saga, another use case for GLP-1s, and a hurdle in Verve’s gene editing plans.
Here’s where you ... Show More
Sep 24
The FDA's Overton era, and dispatches from Shanghai
"The Readout LOUD" is going international this week. STAT's Jason Mast joins the podcast from Shanghai, where he's digging into what the rise of Chinese drug development means for the biotech industry. The hosts also speak to colleague Margaret Manto about Heidi Overton, the pres ... Show More
29m 41s
Sep 17
Definium's new psychedelics data, and a reprieve for international scientists
International researchers got a reprieve in the courts this week. But many are still considering leaving the states for opportunities elsewhere. What does that mean for the future of American medical research? We discuss that, plus the latest news in the life sciences, on this we ... Show More
28m 17s
Jun 2024
Leading with science: A deep dive on biotech
In this episode, David Lebovitz, Global Strategist, Multi-Asset Solutions, is joined by Stephen Squinto, Chief Investment Officer, J.P. Morgan Life Sciences Private Capital, to discuss the alternative investment landscape, the private biotech market and areas of opportunity in 20 ... Show More
17m 43s
Jan 2021
Wall St. Reviving Dream of Bitcoin ETF
Dr. Ken Redcross, Founder of Redcross Concierge, discusses Covid vaccines and communities most at risk. Bloomberg CityLab Reporter Kriston Capps talks about the story “Trump Has One Last Chance to Meddle With Census Numbers.” John Fieldly, CEO at Celsius Holdings, talks about the ... Show More
40m 13s